Three years after FDA approval of the first CAR-T therapy, Dr. Grupp will review outcomes data and provide an update on advancements and new trials in the field of cancer immunotherapy for patients with relapsed acute lymphoblastic leukemia (ALL).
In this lecture, we will provide an overview for general practitioners and hematologists in which we review limitations of current therapies for sickle cell disease, pivotal data leading to the emergence of novel therapies, and approaches to deciding which therapies are optimal for individual patients.
During this webinar, we will present the general approach to patients with a possible cancer predisposition syndrome, review a few of the more common cancer surveillance syndromes, and discuss future directions in the field of pediatric cancer predisposition.
Optic pathway gliomas (OPGs) are low-grade astrocytomas that occur in 15-20% of children with neurofibromatosis type 1 (NF1). Although rarely life-threatening, these tumors can cause significant vision loss. Given this, the main goal of management is to reduce the risk of permanent visual loss.
Join us as we highlight breaking research in pediatric cardiology and explore the latest developments in our ever-expanding field.
In this lecture, we will cover the evolution of modern-era multi-modality therapy for children with the most common extra-cranial solid tumor of childhood.